Literature DB >> 22498076

Schizophrenia with preserved insight is associated with increased perfusion of the precuneus.

Catherine Faget-Agius1, Laurent Boyer, Romain Padovani, Raphaëlle Richieri, Olivier Mundler, Christophe Lançon, Eric Guedj.   

Abstract

BACKGROUND: Preserved insight into illness has been suggested to be predictive of outcome in patients with schizophrenia. We aimed to investigate the functional substrate underlying preserved insight in these patients.
METHODS: We recruited patients with paranoid schizophrenia and healthy controls matched for age and sex. Patients were grouped according to preserved or impaired insight into illness using the Scale to assess Unawareness of Mental Disorder (SUMD). Whole-brain technetium-99m ethyl cysteinate dimer single photon emission computed tomography regional cerebral blood flow was compared at the voxel level between the 2 groups using a statistical parametric map (voxel-level significance of p < 0.001, uncorrected; cluster level significance of p < 0.05, uncorrected).
RESULTS: We enrolled 31 right-handed patients with schizophrenia and 18 controls in our study. Twenty-one (67.7%) patients had preserved insight. The 2 groups did not differ significantly in demographic and clinical characteristics or in treatment. Compared with controls, the whole group of patients showed bilateral frontotemporal hypoperfusions, with no statistical difference between patients with preserved or impaired insight for these areas. Patients with preserved insight showed significantly increased perfusion of the bilateral precuneus relative to those with impaired insight. LIMITATIONS: Patients with subtypes other than paranoid schizophrenia have to be investigated to assess whether involvement of the precuneus in patients with preserved insight can be identified across the full spectrum of subtypes and symptoms of schizophrenia. Moreover, our study concerned only the central dimension (awareness of mental disorder) of 1 scale (SUMD); other dimensions of insight could be studied.
CONCLUSION: Our results show that schizophrenia with preserved insight is associated with greater perfusion of the precuneus, a brain area known to be involved in self- consciousness, suggesting a compensatory mechanism of fronto-temporal impairment.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22498076      PMCID: PMC3447128          DOI: 10.1503/jpn.110125

Source DB:  PubMed          Journal:  J Psychiatry Neurosci        ISSN: 1180-4882            Impact factor:   6.186


  66 in total

1.  Reflective self-awareness and conscious states: PET evidence for a common midline parietofrontal core.

Authors:  Troels W Kjaer; Markus Nowak; Hans C Lou
Journal:  Neuroimage       Date:  2002-10       Impact factor: 6.556

2.  Antipsychotic treatment beyond antipsychotics: metacognitive intervention for schizophrenia patients improves delusional symptoms.

Authors:  S Moritz; R Veckenstedt; S Randjbar; F Vitzthum; T S Woodward
Journal:  Psychol Med       Date:  2011-01-28       Impact factor: 7.723

3.  Cognitive training of verbal memory using a dichotic listening paradigm: impact on symptoms and cognition.

Authors:  J M Fiszdon; H Whelahan; G J Bryson; B E Wexler; M D Bell
Journal:  Acta Psychiatr Scand       Date:  2005-09       Impact factor: 6.392

4.  Does insight affect long-term impatient treatment outcome in chronic schizophrenia?

Authors:  R C Schwartz; B N Cohen; A Grubaugh
Journal:  Compr Psychiatry       Date:  1997 Sep-Oct       Impact factor: 3.735

5.  Functional imaging of 'theory of mind'

Authors:  Helen L. Gallagher; Christopher D. Frith
Journal:  Trends Cogn Sci       Date:  2003-02       Impact factor: 20.229

6.  Insight as a predictor of the outcome of first-episode nonaffective psychosis in a prospective cohort study in England.

Authors:  Richard J Drake; Graham Dunn; Nick Tarrier; Richard P Bentall; Gillian Haddock; Shôn W Lewis
Journal:  J Clin Psychiatry       Date:  2007-01       Impact factor: 4.384

7.  The posterior superior temporal sulcus is involved in social communication not specific for the eyes.

Authors:  Simone Materna; Peter W Dicke; Peter Thier
Journal:  Neuropsychologia       Date:  2008-05-23       Impact factor: 3.139

8.  Follow-up of pain processing recovery after ketamine in hyperalgesic fibromyalgia patients using brain perfusion ECD-SPECT.

Authors:  Eric Guedj; Serge Cammilleri; Cécile Colavolpe; Catherine de Laforte; Jean Niboyet; Olivier Mundler
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-21       Impact factor: 9.236

9.  A comparison between an interview and a self-report method of insight assessment in chronic schizophrenia.

Authors:  Donald A Young; Zachariah Campbell; Konstantine K Zakzanis; Earl Weinstein
Journal:  Schizophr Res       Date:  2003-09-01       Impact factor: 4.939

Review 10.  Chlorpromazine equivalent doses for the newer atypical antipsychotics.

Authors:  Scott W Woods
Journal:  J Clin Psychiatry       Date:  2003-06       Impact factor: 4.384

View more
  19 in total

1.  Metacognition: towards a new approach to quality of life.

Authors:  Julien Blanc; Laurent Boyer; Pierre Le Coz; Pascal Auquier
Journal:  Qual Life Res       Date:  2013-08-29       Impact factor: 4.147

2.  Denial in methamphetamine users: Associations with cognition and functional connectivity in brain.

Authors:  Andy C Dean; Milky Kohno; Angelica M Morales; Dara G Ghahremani; Edythe D London
Journal:  Drug Alcohol Depend       Date:  2015-03-18       Impact factor: 4.492

3.  A brain-wide association study of DISC1 genetic variants reveals a relationship with the structure and functional connectivity of the precuneus in schizophrenia.

Authors:  Xiaohong Gong; Wenlian Lu; Keith M Kendrick; Weidan Pu; Chu Wang; Li Jin; Guangmin Lu; Zhening Liu; Haihong Liu; Jianfeng Feng
Journal:  Hum Brain Mapp       Date:  2014-06-07       Impact factor: 5.038

4.  Alterations in hippocampal connectivity across the psychosis dimension.

Authors:  Niyatee Samudra; Elena I Ivleva; Nicholas A Hubbard; Bart Rypma; John A Sweeney; Brett A Clementz; Matcheri S Keshavan; Godfrey D Pearlson; Carol A Tamminga
Journal:  Psychiatry Res       Date:  2015-06-16       Impact factor: 3.222

5.  Abnormal Grey Matter Arteriolar Cerebral Blood Volume in Schizophrenia Measured With 3D Inflow-Based Vascular-Space-Occupancy MRI at 7T.

Authors:  Jun Hua; Allison S Brandt; SeungWook Lee; Nicholas I S Blair; Yuankui Wu; Su Lui; Jaymin Patel; Andreia V Faria; Issel Anne L Lim; Paul G Unschuld; James J Pekar; Peter C M van Zijl; Christopher A Ross; Russell L Margolis
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

6.  Neurobiology of insight deficits in schizophrenia: An fMRI study.

Authors:  Mujeeb U Shad; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2015-05-06       Impact factor: 4.939

Review 7.  Systematic review reveals heterogeneity in the use of the Scale to Assess Unawareness of Mental Disorder (SUMD).

Authors:  Rémy Dumas; Karine Baumstarck; Pierre Michel; Christophe Lançon; Pascal Auquier; Laurent Boyer
Journal:  Curr Psychiatry Rep       Date:  2013-06       Impact factor: 5.285

8.  Neurocognition, insight and medication nonadherence in schizophrenia: a structural equation modeling approach.

Authors:  Laurent Boyer; Michel Cermolacce; Daniel Dassa; Jessica Fernandez; Mohamed Boucekine; Raphaelle Richieri; Florence Vaillant; Remy Dumas; Pascal Auquier; Christophe Lancon
Journal:  PLoS One       Date:  2012-10-29       Impact factor: 3.240

Review 9.  Disturbance of intentionality: a phenomenological study of body-affecting first-rank symptoms in schizophrenia.

Authors:  Dusan Hirjak; Thiemo Breyer; Philipp Arthur Thomann; Thomas Fuchs
Journal:  PLoS One       Date:  2013-09-03       Impact factor: 3.240

10.  Improvement of health-related quality of life in depression after transcranial magnetic stimulation in a naturalistic trial is associated with decreased perfusion in precuneus.

Authors:  Rémy Dumas; Raphaëlle Richieri; Eric Guedj; Pascal Auquier; Christophe Lancon; Laurent Boyer
Journal:  Health Qual Life Outcomes       Date:  2012-07-28       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.